First-Line Chemotherapy for Advanced Breast Cancer

Abstract

References

Greenspan

E.M.

. Results of four drug sequential combination chemotherapy of breast cancer in relation to predominant organ metastases. Proc Annu Meet Am Assoc Cancer Res. 1965; 6: 24. Abstract.

A'Hern

R.P.

, Smith

I.E.

, Ebbs

S.R.

. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer. 1993; 67: 801–805.

Fossati

, Confalonieri

, Torri

. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998; 16: 3439–3460.

Greenberg

P.A.

, Hortobagyi

G.N.

, Smith

T.L.

. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996; 14: 2197–2205.

Sledge

G.W.

, Neuberg

, Ingle

. Phase III trial of doxorubicin (A) versus paclitaxel (T) versus doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 1a. Abstract 2.

Fornier

, Seidman

A.D.

, Esteva

F.J.

. Weekly (W) Herceptin (H) + 1 hour Taxol (T): phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2–) metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 482a. Abstract.

Perez

E.A.

, Irwin

D.H.

, Patel

. A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 480a. Abstract.

Sikov

, Akerley

, Strenger

. Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC). Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 432a. Abstract.

Löffler

T.M.

, Freund

, Dröge

. Activity of weekly Taxotere (txt) in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 435a. Abstract.

10.

Hryniuk

, Bush

. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2: 1281–1288.

11.

Rahman

Z.U.

, Frye

D.K.

, Buzdar

A.U.

. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997; 15: 3171–3177.

12.

Bezwoda

W.R.

. Primary high dose chemotherapy for metastatic breast cancer: update and analysis of prognostic factors. Proc Annu Meet Am Soc Clin Oncol. 1998; 17: 445a. Abstract.

13.

Stadtmauer

E.A.

. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluor ouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the Philadelphia Intergroup Study (PBT-01). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 1a. Abstract.